Eberlein T J, Rosenstein M, Rosenberg S A
J Exp Med. 1982 Aug 1;156(2):385-97. doi: 10.1084/jem.156.2.385.
We have studied the ability of immunized lymphoid cells expanded in IL-2 to mediate the cure of mice with localized and disseminated syngeneic lymphoma. Mice received 500 rad total-body irradiation before injection of tumor into the footpad. Mice were treated 5 d later when a palpable local tumor and disseminated metastases were present. Intravenous injection of in vivo immune lymphocytes cured 93% of all mice, significantly better than any control group (P less than 0.0005). Immune cells, secondarily sensitized to the FBL-3 tumor in vitro, also conferred significant survival benefit (P less than 0.005) when injected intravenously, curing 79% of the animals treated. When these in vitro sensitized cells were expanded in IL-2, 8-10-fold over 7 d, 93% of the animals thus treated were cured, (P less than 0.005). When these cells were grown for multiple generations in IL-2 they retained their ability to cure mice (56% cured, P less than 0.01). This is the first demonstration that intravenous injection of sensitized cells grown in long term culture in IL-2 is capable of curing mice of established local and disseminated syngeneic tumor.
我们研究了在白细胞介素-2（IL-2）中扩增的免疫淋巴细胞介导治愈患有局部和播散性同基因淋巴瘤小鼠的能力。小鼠在将肿瘤注射到足垫前接受500拉德全身照射。当出现可触及的局部肿瘤和播散性转移时，于5天后对小鼠进行治疗。静脉注射体内免疫淋巴细胞治愈了所有小鼠中的93%，显著优于任何对照组（P小于0.0005）。在体外对FBL-3肿瘤再次致敏的免疫细胞静脉注射时也带来了显著的生存益处（P小于0.005），治愈了79%接受治疗的动物。当这些体外致敏细胞在IL-2中扩增7天达到8至10倍时，93%接受如此治疗的动物被治愈（P小于0.005）。当这些细胞在IL-2中传代培养多代后，它们仍保留治愈小鼠的能力（56%被治愈，P小于0.01）。这首次证明静脉注射在IL-2中长期培养生长的致敏细胞能够治愈患有已形成的局部和播散性同基因肿瘤的小鼠。
